CG
XLRN

Cutler Group’s Acceleron Pharma XLRN Stock Holding History

Cutler Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-71,931
Closed -$12.4M – 6531
2021
Q3 		$12.4M Buy
71,931
+70,893
+6,830% +$9.27M 0.56% 21
2021
Q2 		$130K Buy
+1,038
New +$131K 0.01% 1656
2020
Q3 		– Sell
-6,887
Closed -$656K – 5466
2020
Q2 		$656K Buy
6,887
+5,987
+665% +$577K 0.04% 410
2020
Q1 		$80K Sell
900
-2,500
-74% -$194K ﹤0.01% 1464
2019
Q4 		$180K Sell
3,400
-4,000
-54% -$182K 0.01% 878
2019
Q3 		$292K Sell
7,400
-1,500
-17% -$65.1K 0.03% 534
2019
Q2 		$365K Buy
8,900
+4,299
+93% +$178K 0.03% 442
2019
Q1 		$214K Sell
4,601
-300
-6% -$13.2K 0.02% 616
2018
Q4 		$213K Buy
+4,901
New +$245K 0.02% 614
2018
Q1 		– Sell
-39
Closed -$1K – 5565
2017
Q4 		$1K Sell
39
-1,671
-98% -$62.7K ﹤0.01% 4683
2017
Q3 		$63K Buy
+1,710
New +$59.4K ﹤0.01% 2035
2016
Q1 		– Sell
-238
Closed -$6.92K – 7469
2015
Q4 		$11K Buy
+238
New +$8.56K ﹤0.01% 4083

Cutler Group's XLRN Position: Q4 2021 in Review

Cutler Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 71,931 shares — an estimated $12.4M sold.

Cutler Group first reported a position in XLRN in Q4 2015 and held it in 12 quarters. The position peaked at $12.4M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Cutler Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 71,931 Acceleron Pharma shares in Q4 2021, an estimated $12.4M.
  • Cutler Group first reported a position in Acceleron Pharma in Q4 2015 and held it in 12 quarters.
  • Cutler Group's Acceleron Pharma position peaked at $12.4M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.